Previous Statements by NKTR
» Nektar CEO Discusses Q3 2010 Results - Earnings Call Transcript
» Nektar Therapeutics Q2 2010 Earnings Call Transcript
» Nektar Therapeutics Q1 2010 Earnings Call Transcript
IntelliPharmaceuticals has a bio-equivalent to OxyContin, but says it is harder to tamper with. The pharma company is hoping to gain a recommendation from an FDA committee on Wednesday.
NeuroDerm, Novavax and Nektar Therapeutics were among the biotech stock movers in premarket trading on July 24.
Puma Biotechnology, Nektar Therapeutics and Paratek Pharmaceuticals were among the biotech movers in premarket trading on July 18.
NKTR-181 is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids.
Huge profits could be on the doorstep for these hot breakout setups.